Source of Zhuhai Kerui Biotechnology

{{Infobox organisation | name = Zhuhai Kerui Biotechnology Co., Ltd. | subtitle = Organisation | image = facility.svg | caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | Legal name = Zhuhai Kerui Biotechnology Co., Ltd. | Trading name = KP | Other designations = KP Biotech, Zhuhai Kerui Biotechnology <!-- Identity --> | Founded = 2016 | Headquarters = Zhuhai, China | Industry = Research-compound supply | Shop domain = [https://keruipeptides.com/ Visit KP] <!-- Products and documentation --> | Product scope = peptides, SARMs, injectable oils and raw materials | Catalogue size = 350+ listings (self-reported) | Documentation = Batch certificate of analysis reported with orders | Independent reports = Submitted to this wiki by purchasers; see §Independent testing record <!-- PeptidePedia reception tally --> | Submissions = 791 to July 2026 | Evidence quality = '''Weak''' — self-selected, self-reported }} {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} {{primarysources|date=July 2026|talk=Method disclosure: are we writing an endorsement?}} '''Zhuhai Kerui Biotechnology Co., Ltd.''' (trading as '''KP'''; keruipeptides.com) is a research-peptide supplier trading as KP from Zhuhai, Guangdong, China, incorporated in 2016, supplying research peptides and related materials with batch documentation and tracked international shipping.{{r|registry,selfpub}} The organisation is one of twenty covered on PeptidePedia under [[Project:Vendor notability]]. Like the others, it distributes material labelled [[Research use only|for research use only]], which is '''not approved for human use''' in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.{{r|ruo}} This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by [[Janoshik Analytical]], [[Medutest]], [[PeptideMeter]] and [[VendorInvestigate]].{{r|tally}} == Corporate identity and history == Incorporated in 2016 in Zhuhai, on the western side of the Pearl River Delta adjacent to Macau, the organisation operates from one of China's more established special economic zones.{{r|registry}} The location has a practical consequence visible in purchaser reports: outbound shipments frequently route through Hong Kong or Macau, and reported transit times to Europe and North America have been among the shorter in this set.{{r|reports}} The documentary base is the registry record, the organisation's own material and purchaser reports. No independent coverage has been identified, and the article says nothing about capability that rests only on self-published claims. == Distribution and dispatch == The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. == Operations and documentation practice == Reports describe lyophilised material in crimped glass vials with a batch certificate reporting purity, appearance and, in most of the submitted set, a water content.{{r|reports}} Insulated packaging with a gel pack is described for the incretin lines. One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity|area percent]] depends on the separation that produced it.{{r|usp1503}} == Product range == | Class | Representative listings | Documentation reported | |---|---|---| | Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate with method, purity, water | | Research peptides | Repair and secretagogue peptides | Certificate with method | | SARMs | Bulk | Certificate, purity | | Raw materials and oils | Bulk | Certificate, limited detail | Method disclosure on the peptide lines is the distinguishing documentation feature. It does not make the figure correct; it makes it checkable, which is a different and more useful property.{{r|usp1503}} == Independent testing record == Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r|reports}} Where method conditions match, agreement between an independent report and a certificate is a meaningfully stronger observation than where they do not — much of the routine disagreement between two purity figures is attributable to different columns and integration parameters rather than to different material.{{r|usp1503}} == Reception == The PeptidePedia tally records 791 self-reported submissions to July 2026. Recurring positive themes are certificate detail, method disclosure and transit time; recurring complaints concern documentation on the bulk lines.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} === How this tally should be read === The reception figure above is a mean of self-reported submissions to PeptidePedia. It is '''weak evidence''' and is subject to three limitations that apply to every such figure on this wiki: * '''Self-selection.''' People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions. * '''It measures reception, not quality.''' Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly. * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.{{r|tally}} == Regulatory position and legal status == The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} Material labelled [[Research use only|for research use only]] is outside the regulatory framework that governs medicines. Its identity, purity, sterility and [[Bacterial endotoxin test|endotoxin]] content are not assured by any regulator, and a [[Certificate of analysis|certificate of analysis]] issued by a supplier is a claim by that supplier rather than an independent finding.{{r|ruo,usp1503}} Import of such material for personal use is unlawful or restricted in many jurisdictions, and [[Customs seizure|seizure]] is a documented outcome. PeptidePedia describes the legal position and does not advise on it.{{r|ruo}} == Notability and coverage == This article exists because the organisation satisfies at least three of the five criteria at [[Project:Vendor notability]]. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.{{r|registry,selfpub,reports}} What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} Two frameworks are named in this article only to say what has ''not'' been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,{{r|gmp}} and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.{{r|iso17025}} Neither assessment is available here for this organisation or for any other covered on this wiki. The article's talk page carries the notability discussion in full, including the standing question of whether entities with no distinguishing features warrant separate articles at all. == External links == * [https://keruipeptides.com/ Visit KP] == References == {{reflist}} <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> == Further reading == * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. == See also == * [[Certificate of analysis]] * [[Third-party testing]] * [[Area percent purity]] * [[Peptide content]] * [[Research use only]] * [[Peptide supply chain]] * [[Blind sampling]] {{DEFAULTSORT:Zhuhai Kerui Biotechnology}} [[Category:Peptide suppliers]] [[Category:Suppliers in China]] [[Category:Certificates of analysis]] [[Category:Testing methodology]]